Shares of ClearOne surged to $4.65 in early trading Wednesday after Vivani Medical confirmed it expects to price and close its reverse merger — a deal that would fold Cortigent, its brain-implant subsidiary, into ClearOne — by October 2026. The move gives investors a concrete date for a transaction that has been looming for months, but the strategic logic remains as unusual as ever. ClearOne Pops 11% on Merger Countdown, but Will Existing Shareholders Be Left Holding a Sliver of a Speculative Neurotech Bet?
Shares of ClearOne (CLRO) jumped 11% to $4.65 Wednesday after Vivani Medical confirmed it now expects to price and close its reverse merger — folding brain-implant subsidiary Cortigent into ClearOne's Nasdaq shell — in October 2026 . The deal, originally slated for Q3, is running slightly behind schedule but finally has a concrete landing date. For shareholders of a company with almost no operating business left, the question is whether the timeline clarity justifies the rally — or masks a punishing dilution event weeks away.
ClearOne Is Essentially a Corporate Shell Awaiting a New Tenant. Yahoo Finance now describes ClearOne as a company that "does not have significant operations," noting it was previously engaged in audio and video collaboration solutions.
Annual revenue collapsed to $11.4 million in 2024, down 39% year-over-year , and as of June 30, 2026, the company carried an accumulated deficit of $37.5 million and negative total shareholders' equity of -$381,000 . The stock's utility is its Nasdaq listing, not its business.
Current Shareholders Will Own a Thin Slice of Whatever Comes Next. After the merger closes, Vivani will own 59.4% to 67.5% of the combined company, while legacy ClearOne shareholders will hold just 12.7% to 14.4% . On top of that, ClearOne agreed to raise $10 million to $15 million through a new share offering at closing , which will dilute existing holders further. Shareholders have already been substantially diluted — shares outstanding grew 54% in the past year.
The New Identity Is a Pre-Revenue Brain-Implant Maker. ClearOne will be renamed "Cortigent Holdings" and trade under ticker CRGT . Cortigent, descended from Second Sight Medical, is developing neurostimulation systems to restore vision and potentially muscle movement — ambitious science, but with no commercial revenue and Vivani itself posting negative EBITDA (a measure of operating cash burn) of $26.9 million over the past twelve months .
The Deal Still Needs Several Boxes Checked. Closing conditions include stockholder approvals, completion of the financing, minimum net cash requirements, and continued Nasdaq listing . ClearOne's own SEC filing warns: "There can be no assurance that the Merger…will be completed on the anticipated terms, or at all."
Today's pop is a bet on deal certainty, not fundamentals. Investors buying here are wagering that a speculative neurotech story is worth more inside a newly capitalized Nasdaq wrapper than ClearOne's deteriorating audio legacy ever was.